3/3/15. UBS initiates coverage with a sell rating. I agree. Statistically cheap, below book value, but deteriorating fundamentals. Depositors are fleeing as Zion desperately tries to boost fee income. Apparently they have forgotten who keeps them in business.
After AH closed , late in night, ABBVIE out bid JNJ by offering $261 for PCYC.....we should have exciting day in Biotechs tomorrow. Analysts were so wrong on value of PCYC...Lets get INCY higher !!!!!
Biotechpicklist released a "hack" piece called "Advaxis Is A Biotechnology Company That Should Be Avoided For Now" Nothing but negative innuendo and twisted facts. Hopefully, our more astute board members (Justice, China etc) will chime in and set the record straight. It amazes me how these nobody analysts come out of the woodwork and think they are smarter than all the BP and investment firms we're associated with.
Ughhh, I hope this newest trash doesn't bring rdmikes and his ilk back to the board!!
Sentiment: Strong Buy
Why not let the courts decide before you render your EXPERT judgment. But, the PR associated with PLUG is not good...
at between 30 and 50 million peak sales revenues
to IntelGenx from what I understand. That is 30 to
50 million for "each" of their contracted VersaFilm
products which currently there are three.
H.C. Wainwright places it's $2.00 price target on Forfivo XL
sales revenues alone which they projected would take the
company profitable. Recently Wainwright re-stated their
$2.00 share price target due to IntelGenx coming to
profitability "earlier than expected", end of 2015 instead
of the previously estimated 2016.
Wainwright also did not recognize 45O milestones
into the equation either if I'm not mistaken. Those
milestones are like golden eggs when before they
were just forgotten geese.
Everybody needs to do their own due diligence
and put on their big-boy pants.
...and buckle up. Volatility and wealth creation coming.
Sentiment: Strong Buy
Right, Motley Fools - I guess if they say it then it must be true! Their continued negativity is second only to Another Fartstain/the Street.
There are five months to go before the real breakout starts.
Tony Continues garbage posts containing only his favorite letter: "F"
No surprise there. It's the first letter in Tony's favorite word, and it's the letter that was most commonly used in his high-school report card.
Unlike the company's Sovaldi, which won’t be paid for until the summer
Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.
I think these analysts think they've got it all figured out after they "study" the market for about two hours reading a couple of research reports and joining a few conference calls from companies in the category, and then BAM - there's their sage opinion. I can say with confidence that if you take the collective time that "the six figure club" on this board has spent studying ACHN and this market, it would make Mr. High-and-Mighty- Barclay analyst look like an amateur. There's a reason why so many analysts are a) flat out wrong, b) late to the party, and c) completely off-base on their price targets. Most analysts, just like most hedge fund managers, do no better than and often worse than the market. The only difference in street cred is that they've got a "brand" behind their (often worthless) opinion.